{
    "symbol": "BTCY",
    "quarter": 2,
    "year": 2023,
    "date": "2022-11-14 21:54:04",
    "content": " Our leading revenue driver in the second quarter continued to be Bioflux, our high-precision single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient's ambulatory ECG diagnostics. For the three months and six months ending September 30, 2022 our combined device sales and technology fee income totaling $2.4 million and $4.4 million, representing an increase of 32% and 24% compared to the corresponding period year prior, showcasing our year-over-year growth and validating our recent strategic initiatives."
}